Public Market Listing
Live quotes, historical charts, and market capitalization for Kissei Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
fostamatinib(Tavalisse) | Approved | Spleen tyrosine kinase (Syk)Small molecule | Immune Thrombocytopenia |
| Approved | Mutant IDH1Small molecule | Acute Myeloid LeukemiaGlioma Relapsed/Refractory Acute Myeloid Leukemia | |
Sucroferric oxyhydroxide(Velphoro) | Approved | Dietary phosphateSmall molecule | Chronic Kidney DiseaseHyperphosphatemia |
JR-131No recent activity | Phase 3 | Erythropoietin receptor (EPO-R)Biologic (subtype unspecified) | Chronic Kidney Disease |
Mitiglinide(Glufast) | Phase 3 | SUR1 (short-acting)Small molecule | Type 2 Diabetes |
Omarigliptin(Marizev) | Phase 3 | DPP-4Small molecule | Indication not yet linked |
| Phase 2 | D2/D3Small molecule | Parkinson's Disease |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
June 2029 (1)
What to watch
2030 (1)
September 2030 (1)
What to watch
Financial reports
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| FY2026 | $595M | — | $330M | — | report ↗ |